Suppr超能文献

25 年骨髓恶性肿瘤的流行病学记录:来自科多尔血液恶性肿瘤专科登记处(法国勃艮第)的数据。

Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).

机构信息

Registre des Hémopathies Malignes de Côte d'Or, EA 4184, Faculté de Médecine, Dijon Cedex, France.

出版信息

Haematologica. 2011 Jan;96(1):55-61. doi: 10.3324/haematol.2010.026252. Epub 2010 Oct 22.

Abstract

BACKGROUND

Epidemiological data on myeloid malignancies are very rare in the literature due to a lack of registration by cancer registries until 2000. The Registry of Hematologic Malignancies of the Côte d'Or Department in France has, however, steadfastly registered data on cases occurring in the Department since 1980, resulting, to date, in a database of over 5,000 cases classified according to the ICD-O-3 classification, following the most recent World Health Organization classification criteria.

DESIGN AND METHODS

Twenty-five years of data on myeloid malignancies, including acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative syndromes were analyzed. World population standardized incidence rates were calculated as were as observed and relative survival.

RESULTS

Incidence rates per 100,000 inhabitants/year were 2.5 for acute myeloid leukemia, 1.3 for myelodysplastic syndromes, 3.2 for myeloproliferative neoplasms and 0.6 for myelodysplastic/myeloproliferative syndromes. It was found that the incidence rate of myelodysplastic syndromes increased significantly over the period. The median overall survival is 8.9 months for patients with acute myeloid leukemia, 33.8 months for patients with myelodysplastic syndromes, 91.7 months for those with myeloproliferative neoplasms and 26.6 months for patients with myelodysplastic/myeloproliferative syndromes. Observed and relative 20-year survival rates are, respectively, 12% and 13% in acute myeloid leukemia, 2% and 6% in myelodysplastic syndromes and 20% and 34% in myeloproliferative neoplasms.

CONCLUSIONS

These population-based data on myeloid malignancies are the first data collected over such a long period and provide interesting information for clinicians and public health authorities, particularly given the paucity of other long-term, population-based data from cancer registries.

摘要

背景

由于癌症登记处直到 2000 年才对髓系恶性肿瘤进行登记,因此文献中很少有关于髓系恶性肿瘤的流行病学数据。然而,法国科多尔部门血液恶性肿瘤登记处自 1980 年以来一直在该部门登记病例数据,迄今为止,已根据最新的世界卫生组织分类标准,根据 ICD-O-3 分类对超过 5000 例病例进行了分类,建立了一个数据库。

设计和方法

分析了 25 年来髓系恶性肿瘤(包括急性髓系白血病、骨髓增生性肿瘤、骨髓增生异常综合征和骨髓增生异常/骨髓增生性肿瘤)的数据。计算了每 10 万居民的标准化发病率,以及观察生存率和相对生存率。

结果

每年每 10 万居民的发病率分别为急性髓系白血病 2.5 例、骨髓增生异常综合征 1.3 例、骨髓增生性肿瘤 3.2 例和骨髓增生异常/骨髓增生性肿瘤 0.6 例。结果发现,骨髓增生异常综合征的发病率在这期间显著增加。急性髓系白血病患者的中位总生存期为 8.9 个月,骨髓增生异常综合征患者为 33.8 个月,骨髓增生性肿瘤患者为 91.7 个月,骨髓增生异常/骨髓增生性肿瘤患者为 26.6 个月。观察生存率和相对 20 年生存率分别为急性髓系白血病 12%和 13%、骨髓增生异常综合征 2%和 6%、骨髓增生性肿瘤 20%和 34%。

结论

这些基于人群的髓系恶性肿瘤数据是此类长期数据的首次收集,为临床医生和公共卫生当局提供了有趣的信息,特别是考虑到癌症登记处其他长期基于人群的数据很少。

相似文献

6
Incidence, survival and prevalence of myeloid malignancies in Europe.欧洲髓系恶性肿瘤的发病率、生存率和流行率。
Eur J Cancer. 2012 Nov;48(17):3257-66. doi: 10.1016/j.ejca.2012.05.024. Epub 2012 Jul 4.
8
Therapy-related myeloid neoplasms following treatment with radioiodine.放射性碘治疗后相关的骨髓增生性肿瘤。
Haematologica. 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.

引用本文的文献

7
Mouse Models of CMML.CMML 的小鼠模型。
Int J Mol Sci. 2021 Oct 26;22(21):11510. doi: 10.3390/ijms222111510.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验